There was no consistent evidence that eptifibatide increased the risk of major or minor bleeding associated with tissue plasminogen activator in either a PCI or an acute myocardial infarction study; however, eptifibatide appeared to increase the risk of bleeding when administered with streptokinase in an acute myocardial infarction study.